Literature DB >> 12634965

99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Alessio Annovazzi1, Livia Biancone, Renato Caviglia, Marco Chianelli, Gabriela Capriotti, Stephen J Mather, Renzo Caprilli, Francesco Pallone, Francesco Scopinaro, Alberto Signore.   

Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease that may involve the whole gut. Marked intestinal T cell and macrophage activation is a key feature of the disease. Polymorphonuclear cell infiltration is also observed in the diseased gut, mainly during active inflammation. Scintigraphic detection of granulocytes and activated lymphocytes infiltrating the gut wall may be useful in identifying a subgroup of patients with clinically inactive CD who are undergoing early clinical relapse. The aims of the present study were (a) to compare the effectiveness of scintigraphy with (99m)Tc-labelled interleukin-2 ((99m)Tc-IL2) and with (99m)Tc-HMPAO labelled granulocytes ((99m)Tc-WBC) in detecting the presence and extent of bowel inflammation in patients with long-term inactive CD (>12 months) and (b) to assess the accuracy of these techniques in predicting future disease relapse. We studied 29 patients with ileal and/or colonic CD in stable clinical remission (Crohn's Disease Activity Index <150 for at least 12 months) using both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy in order to evaluate the extent of acute and chronic inflammation in the bowel. Planar and single-photon emission tomography images were acquired in each patient at 1 h p.i. For quantitative analysis of (99m)Tc-IL2 uptake, the abdomen was divided into 32 regions of interest. Despite the absence of symptoms, 18 patients (62%) showed a positive (99m)Tc-IL2 and 18 (62%) a positive (99m)Tc-WBC scan. Only 12 patients (41.4% of the total group) were positive on both scans, and the sites of IL2 and granulocyte bowel uptake were usually located in different segments, indicating that in CD, acute and chronic inflammation can be present in different sites. As far as the prognostic role of the two scans in predicting future disease relapse is concerned, both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy showed a high negative predictive value (1.00 and 0.91, respectively) but a weak positive predictive value (0.44 and 0.39, respectively). Nevertheless, Kaplan-Meier curves generated between scintigraphic findings and time free from disease relapse were statistically different only for (99m)Tc-IL2 scintigraphy (log-rank test, P=0.013). These results indicate that (99m)Tc-IL2 scintigraphy can be useful in selecting CD patients in clinical remission who could benefit from preventive therapy to avoid disease relapse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634965     DOI: 10.1007/s00259-002-1069-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

Review 1.  Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

Authors:  I D R Arnott; D Watts; S Ghosh
Journal:  Aliment Pharmacol Ther       Date:  2002-05       Impact factor: 8.171

2.  Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet.

Authors:  A Signore; M Chianelli; A Annovazzi; M Rossi; L Maiuri; M Greco; G Ronga; K E Britton; A Picarelli
Journal:  Eur J Nucl Med       Date:  2000-01

3.  A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE)

Authors:  M Roca; J Martín-Comín; W Becker; M Bernardo-Filho; B Gutfilen; A Moisan; M Peters; E Prats; M Rodrigues; C Sampson; A Signore; H Sinzinger; M Thakur
Journal:  Eur J Nucl Med       Date:  1998-07

4.  Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.

Authors:  F Pallone; S Fais; O Squarcia; L Biancone; P Pozzilli; M Boirivant
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

5.  Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.

Authors:  W Reinisch; C Gasché; W Tillinger; J Wyatt; C Lichtenberger; M Willheim; C Dejaco; T Waldhör; S Bakos; H Vogelsang; A Gangl; H Lochs
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

6.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

7.  Value of technetium-99m HMPAO-labelled leucocyte scintigraphy as an initial screening test in patients suspected of having inflammatory bowel disease.

Authors:  M H Giaffer; W B Tindale; D Holdsworth
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-12       Impact factor: 2.566

8.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

9.  99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's disease.

Authors:  L Biancone; F Scopinaro; M Ierardi; P Paoluzi; A Marcheggiano; M C Di Paolo; B Porowska; A C Colella; F Pallone
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

10.  Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance.

Authors:  G Sciarretta; A Furno; M Mazzoni; C Basile; P Malaguti
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

View more
  12 in total

1.  Identification of interleukin-2 for imaging atherosclerotic inflammation.

Authors:  Zahi A Fayad; Vardan Amirbekian; Jean-François Toussaint; Valentin Fuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

2.  99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.

Authors:  Alessio Annovazzi; Elena Bonanno; Marcello Arca; Calogero D'Alessandria; Antonella Marcoccia; Luigi G Spagnoli; Francesco Violi; Francesco Scopinaro; Giorgio De Toma; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

3.  Leukocyte-technetium-99m uptake in Crohn's disease: does it show subclinical disease?

Authors:  Luciene G Mota; Luiz G V Coelho; Carlos J R Simal; Maria L A Ferrari; Clodomiro Toledo; Josep Martin-Comin; Simone O F Diniz; Valbert N Cardoso
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Toward Molecular Imaging of Intestinal Pathology.

Authors:  Mariane Le Fur; Iris Y Zhou; Onofrio Catalano; Peter Caravan
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

5.  Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients.

Authors:  Marta Opalinska; Tomasz Stompor; Dorota Pach; Renata Mikolajczak; Danuta Fedak; Marcin Krzanowski; Tomasz Rakowski; Anna Sowa-Staszczak; Boguslaw Glowa; Piotr Garnuszek; Michał Maurin; Urszula Karczmarczyk; Władysław Sulowicz; Alicja Hubalewska-Dydejczyk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

6.  Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.

Authors:  Federico Caobelli; Laura Evangelista; Natale Quartuccio; Demetrio Familiari; Corinna Altini; Angelo Castello; Mariapaola Cucinotta; Rossella Di Dato; Cristina Ferrari; Aurora Kokomani; Iashar Laghai; Riccardo Laudicella; Silvia Migliari; Federica Orsini; Salvatore Antonio Pignata; Cristina Popescu; Erinda Puta; Martina Ricci; Silvia Seghezzi; Alessandro Sindoni; Martina Sollini; Letterio Sturiale; Anna Svyridenka; Vittoria Vergura; Pierpaolo Alongi
Journal:  World J Radiol       Date:  2016-10-28

7.  Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation.

Authors:  Heather Eggleston; Peter Panizzi
Journal:  Informatics (MDPI)       Date:  2014-05-30

8.  99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study.

Authors:  Eef D Telenga; Wim van der Bij; Erik F J de Vries; Erik A M Verschuuren; Wim Timens; Gert Luurtsema; Riemer H J A Slart; Alberto Signore; Andor W J M Glaudemans
Journal:  EJNMMI Res       Date:  2019-05-10       Impact factor: 3.138

9.  Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.

Authors:  Svetomir N Markovic; Filippo Galli; Vera J Suman; Wendy K Nevala; Andrew M Paulsen; Joseph C Hung; Denise N Gansen; Lori A Erickson; Paolo Marchetti; Gregory A Wiseman; Alberto Signore
Journal:  Oncotarget       Date:  2018-07-13

Review 10.  In vivo Imaging Technologies to Monitor the Immune System.

Authors:  Claire E McCarthy; Jordan M White; Nerissa T Viola; Heather M Gibson
Journal:  Front Immunol       Date:  2020-06-02       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.